

Creating a Phase 2 Platform Trial for Obesity Therapies in the UK


What are we doing?

Awarded 12 months of funding by the National Institute for Health and Care Research (NIHR), we aim to develop a novel platform trial based on existing research infrastructure. The platform will have a single point of contracting. A master protocol and a standardised approach will enable multiple individual randomised controlled trials to run at the same time. We will test the weight loss efficacy of new therapies and technologies for children and adults.



Want to shape NHS treatments?

Platform development needs stakeholder input from industry, regulators, healthcare professionals, the public, patients, commercial and NHS research organisations. This platform will lead national testing of pharmaceuticals, medical and digital technology. **Your contributions can shape the future way therapies are tested and prepared for the NHS.**



We want your input to develop a unique platform design to:

- engage with innovators,
- provide optimal cost-efficient phase 2 testing,
- safely and efficiently test obesity innovations (including pharmaceuticals, MedTech and digital technologies)
- effectively manage transition through the testing pipeline,
- support participant engagement, referral and recruitment,
- embed equality, maximise diversity and inclusion,
- minimise participant burden, optimise participant management and retention,
- incorporate high quality data safety, integrity and management,
- provide added value and unique outcomes for industry.



Work with us:



Work with us as a national collaboration led by Oxford, Cambridge and Leicester Biomedical Research Centres (BRC) with specialists in obesity management and mechanisms, Prof Melanie Davies, Prof Sadaf Farooqi and Prof Susan Jebb. Including partners at Bristol and Oxford Health BRCs and supported by the national NIHR Diet and Activity Research Translation Collaboration (DART).